Psychopharmacology Update

Psychopharmacology Update features a licensed and Board Certified Psychiatric Pharmacist (BCPP) presenting an in-depth review over psychiatric medications that have recently been FDA approved. This presentation incorporates an audio-synced slide deck with easy to use functionality to improve the learning experience. This is a scholarly presentation that contains unbiased medication information (NO pharmaceutical sponsorship).


PRESENTATION OBJECTIVES:
Schizophrenia
- describe how antipsychotics affect the pathophysiology of schizophrenia
- identify basic dopamine pathways and their relationship with efficacy vs. side effects
- discuss a unique treatment option for antipsychotic-induced hyperprolactinemia
- examine pharmacological characteristics of 1st and 2nd generation antipsychotics
- discuss differences between the newer antipsychotics
- compare the mean increase in QTc prolongation for individual antipsychotics
- review treatment goals, guidelines for selection, and monitoring
Depression
- discuss unique characteristics of vilazodone (Viibryd™) and vortioxetine (Brintellix™)
- review medication selection
- examine potential receptor targets
- describe the mechanism of antidepressant-induced sexual dysfunction


MEDICATIONS REVIEWED:
Long-Acting Injectable Second Generation Antipsychotics
- aripiprazole monohydrate (Abilify Maintena™)
- olanzapine pamoate (Zyprexa® Relprevv™)
- paliperidone palmitate (Invega® Sustenna®)
- risperidone long-acting injectable (Risperdal® Consta®)

Second Generation Antipsychotic Oral Formulations
- iloperidone (Fanapt®)
- asenapine (Saphris®)
- lurasidone (Latuda®)

First Generation Antipsychotic Inhalation Powder
- loxapine inhalation powder (Adasuve®)

Antidepressants
- vilazodone (Viibryd™)
- vortioxetine (Brintellix™)

All aboard! Come take a journey through the wonderful world of psychopharmacology!!!